QTTB

SEC source: 0000899243-18-009413 · doc4.xml · derivative · entry 5

Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner

Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner

Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner

TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner

V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 989,612 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date.

F2 · shares: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date.

F2 · price: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date.

F2 · derivative.exercise_date: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date.

F2 · derivative.expiration_date: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date.

F2 · ownership.nature: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date.

F6 · ownership.nature: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta.

SEC source: 0000899243-18-009413 · doc4.xml · derivative · entry 4

Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner

Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner

Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner

TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner

V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 1,605,681 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date.

F1 · shares: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date.

F1 · price: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date.

F1 · derivative.exercise_date: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date.

F1 · derivative.expiration_date: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date.

F1 · ownership.nature: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date.

F6 · ownership.nature: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta.

SEC source: 0000899243-18-009413 · doc4.xml · nonDerivative · entry 3

Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner

Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner

Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner

TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner

V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 3,220,293

F5 · ownership.nature: Consists of 625,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $16.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences.

SEC source: 0000899243-18-009413 · doc4.xml · nonDerivative · entry 2

Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner

Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner

Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner

TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner

V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,595,293

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date.

F4 · ownership.nature: Consists of 989,612 shares of Common Stock held of record by TLS Beta.

F6 · ownership.nature: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta.

SEC source: 0000899243-18-009413 · doc4.xml · nonDerivative · entry 1

Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner

Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner

Temasek Life Sciences Private Ltd · CIK 0001379349 · 10% owner

TLS Beta Pte. Ltd. · CIK 0001673754 · 10% owner

V-Sciences Investments Pte Ltd · CIK 0001379350 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,605,681

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date.

F3 · ownership.nature: Consists of 1,605,681 shares of Common Stock held of record by TLS Beta.

F6 · ownership.nature: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta.

SEC source: 0000899243-18-009444 · doc4.xml · derivative · entry 2

Novartis Institutes for BioMedical Research, Inc. · CIK 0001673852 · 10% owner

NOVARTIS AG · CIK 0001114448 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,979,226 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F2 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F2 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

SEC source: 0000899243-18-009444 · doc4.xml · nonDerivative · entry 1

Novartis Institutes for BioMedical Research, Inc. · CIK 0001673852 · 10% owner

NOVARTIS AG · CIK 0001114448 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,979,226

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.direct: The securities reported herein are held of record by Novartis Institutes for BioMedical Research, Inc. ("NIBRI"). NIBRI is an indirect wholly-owned subsidiary of Novartis AG. Novartis AG may therefore be deemed to have or share beneficial ownership of the Common Stock held directly by NIBRI.

SEC source: 0001104659-18-022462 · a4.xml · derivative · entry 3

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,187,535 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock was automatically converted into one share of the Issuer's common stock.

F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock was automatically converted into one share of the Issuer's common stock.

F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock was automatically converted into one share of the Issuer's common stock.

F2 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

SEC source: 0001104659-18-022462 · a4.xml · derivative · entry 2

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 4,204,502 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock was automatically converted into one share of the Issuer's common stock.

F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock was automatically converted into one share of the Issuer's common stock.

F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of Series A Preferred Stock and Series B Preferred Stock was automatically converted into one share of the Issuer's common stock.

F2 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

SEC source: 0001104659-18-022462 · a4.xml · nonDerivative · entry 1

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 6,722,076

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Following the transactions reported herein, includes 6,453,195 shares of Common Stock held of record by 5AM Ventures IV, L.P. ("Ventures IV") and 268,881 shares of Common Stock held of record by 5AM Co-Investors IV, L.P. ("Co-Investors IV").

F2 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

SEC source: 0000899243-18-009447 · doc4.xml · derivative · entry 3

GILLIS STEVEN · CIK 0001229592 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,385,457 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F4 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F4 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F2 · ownership.nature: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F3 · ownership.nature: The Reporting Person is a managing director at ARCH Partners VIII and owns an interest in ARCH Partners VIII but does not have voting or investment control over the shares held by ARCH Fund VIII. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-009447 · doc4.xml · derivative · entry 2

GILLIS STEVEN · CIK 0001229592 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 4,683,238 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F4 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F4 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F2 · ownership.nature: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F3 · ownership.nature: The Reporting Person is a managing director at ARCH Partners VIII and owns an interest in ARCH Partners VIII but does not have voting or investment control over the shares held by ARCH Fund VIII. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-009447 · doc4.xml · nonDerivative · entry 1

GILLIS STEVEN · CIK 0001229592 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 6,068,695

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Following the transactions reported herein, includes 1,196,827 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage") and 4,871,868 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII").

F2 · ownership.nature: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F3 · ownership.nature: The Reporting Person is a managing director at ARCH Partners VIII and owns an interest in ARCH Partners VIII but does not have voting or investment control over the shares held by ARCH Fund VIII. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-009446 · doc4.xml · derivative · entry 3

ARCH Venture Fund VIII, L.P. · CIK 0001605598 · 10% owner

ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner

ARCH Venture Partners VIII, L.P. · CIK 0001616176 · 10% owner

ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

NELSEN ROBERT · CIK 0001219042 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,385,457 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F1 · ownership.nature: Following the transactions reported herein, includes 1,196,827 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage") and 4,871,868 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII").

F2 · ownership.nature: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-009446 · doc4.xml · derivative · entry 2

ARCH Venture Fund VIII, L.P. · CIK 0001605598 · 10% owner

ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner

ARCH Venture Partners VIII, L.P. · CIK 0001616176 · 10% owner

ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

NELSEN ROBERT · CIK 0001219042 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 4,683,238 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F1 · ownership.nature: Following the transactions reported herein, includes 1,196,827 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage") and 4,871,868 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII").

F2 · ownership.nature: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-009446 · doc4.xml · nonDerivative · entry 1

ARCH Venture Fund VIII, L.P. · CIK 0001605598 · 10% owner

ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner

ARCH Venture Partners VIII, L.P. · CIK 0001616176 · 10% owner

ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

NELSEN ROBERT · CIK 0001219042 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 6,068,695

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Following the transactions reported herein, includes 1,196,827 shares of common stock held of record by ARCH Venture Fund VIII Overage, L.P. ("ARCH Fund Overage") and 4,871,868 shares of common stock held of record by ARCH Venture Fund VIII, L.P. ("ARCH Fund VIII").

F2 · ownership.nature: The sole general partner of ARCH Fund VIII is ARCH Venture Partners VIII, L.P. ("ARCH Partners VIII"). The sole general partner of ARCH Partners VIII and ARCH Fund Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"). ARCH Partners VIII may therefore be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH VIII LLC may be deemed to beneficially own the securities held by ARCH Fund VIII and ARCH Fund Overage. ARCH Partners VIII and ARCH VIII LLC disclaim beneficial ownership of such securities, except to the extent of any pecuniary interest therein. The managing directors of ARCH VIII LLC are Keith L. Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VIII and ARCH Fund Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-009459 · doc4.xml · derivative · entry 3

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 659,742 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F2 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F2 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F1 · ownership.nature: The securities reported herein are held of record by Vivo Panda Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D., is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. Each of Vivo LLC and Dr. Shah disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-009459 · doc4.xml · nonDerivative · entry 2

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,159,742

F1 · ownership.nature: The securities reported herein are held of record by Vivo Panda Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D., is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. Each of Vivo LLC and Dr. Shah disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-009459 · doc4.xml · nonDerivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 659,742

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The securities reported herein are held of record by Vivo Panda Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D., is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. Each of Vivo LLC and Dr. Shah disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-009442 · doc4.xml · derivative · entry 3

Rock Springs Capital Management LP · CIK 0001595725 · 10% owner

Rock Springs Capital Master Fund LP · CIK 0001735393 · 10% owner

Rock Springs Capital LLC · CIK 0001735397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 395,845 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F2 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F2 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F1 · ownership.nature: The securities reported herein are held of record by Rock Springs Capital Master Fund LP ("Master Fund"). Rock Springs Capital LLC ("RSC") is the general partner of Rock Springs Capital Management LP ("RSCM") which is the investment manager to Master Fund. RSC and RSCM may therefore be deemed to have or share beneficial ownership of the securities held directly by Master Fund.

SEC source: 0000899243-18-009442 · doc4.xml · nonDerivative · entry 2

Rock Springs Capital Management LP · CIK 0001595725 · 10% owner

Rock Springs Capital Master Fund LP · CIK 0001735393 · 10% owner

Rock Springs Capital LLC · CIK 0001735397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 645,845

F1 · ownership.nature: The securities reported herein are held of record by Rock Springs Capital Master Fund LP ("Master Fund"). Rock Springs Capital LLC ("RSC") is the general partner of Rock Springs Capital Management LP ("RSCM") which is the investment manager to Master Fund. RSC and RSCM may therefore be deemed to have or share beneficial ownership of the securities held directly by Master Fund.

SEC source: 0000899243-18-009442 · doc4.xml · nonDerivative · entry 1

Rock Springs Capital Management LP · CIK 0001595725 · 10% owner

Rock Springs Capital Master Fund LP · CIK 0001735393 · 10% owner

Rock Springs Capital LLC · CIK 0001735397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 395,845

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The securities reported herein are held of record by Rock Springs Capital Master Fund LP ("Master Fund"). Rock Springs Capital LLC ("RSC") is the general partner of Rock Springs Capital Management LP ("RSCM") which is the investment manager to Master Fund. RSC and RSCM may therefore be deemed to have or share beneficial ownership of the securities held directly by Master Fund.

SEC source: 0000899243-18-009495 · doc4a.xml · nonDerivative · entry 1

PARMAR KUSH · CIK 0001664281 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 6,722,076

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Following the transactions reported herein, includes 6,453,195 shares of Common Stock held of record by 5AM Ventures IV, L.P. ("Ventures IV") and 268,881 shares of Common Stock held of record by 5AM Co-Investors IV, L.P. ("Co-Investors IV").

F2 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their recurring interest therein.

F3 · ownership.nature: The Reporting Person is an affiliate of Partners IV and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-009445 · doc4.xml · derivative · entry 3

PARMAR KUSH · CIK 0001664281 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,187,535 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F4 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F4 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F2 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their recurring interest therein.

F3 · ownership.nature: The Reporting Person is an affiliate of Partners IV and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-009445 · doc4.xml · derivative · entry 2

PARMAR KUSH · CIK 0001664281 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 4,204,502 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F4 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F4 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F2 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their recurring interest therein.

F3 · ownership.nature: The Reporting Person is an affiliate of Partners IV and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-009445 · doc4.xml · nonDerivative · entry 1

PARMAR KUSH · CIK 0001664281 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 6,722,076

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Following the transactions reported herein, includes 1,276,838 shares of common stock held of record by 5AM Ventures IV, L.P. ("Ventures IV") and 53,201 shares of common stock held of record by 5AM Co-Investors IV, L.P. ("Co-Investors IV").

F2 · ownership.nature: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their recurring interest therein.

F3 · ownership.nature: The Reporting Person is an affiliate of Partners IV and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0000899243-18-009441 · doc4.xml · derivative · entry 3

Vida Ventures, LLC · CIK 0001724489 · 10% owner

VV Manager LLC · CIK 0001735804 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 395,845 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F2 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F2 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.

F1 · ownership.nature: The securities reported herein are held of record by Vida Ventures, LLC ("Vida"). VV Manager, LLC is the mananging member of Vida. As a result, VV Manager, LLC may be deemed to beneficially own the securities held by Vida. VV Manager, LLC is managed by five directors, each of who disclaim beneficial ownership over the securities held of record by Vida except to the extent of their pecuniary interest therein.

SEC source: 0000899243-18-009441 · doc4.xml · nonDerivative · entry 2

Vida Ventures, LLC · CIK 0001724489 · 10% owner

VV Manager LLC · CIK 0001735804 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 770,845

F1 · ownership.nature: The securities reported herein are held of record by Vida Ventures, LLC ("Vida"). VV Manager, LLC is the mananging member of Vida. As a result, VV Manager, LLC may be deemed to beneficially own the securities held by Vida. VV Manager, LLC is managed by five directors, each of who disclaim beneficial ownership over the securities held of record by Vida except to the extent of their pecuniary interest therein.

SEC source: 0000899243-18-009441 · doc4.xml · nonDerivative · entry 1

Vida Ventures, LLC · CIK 0001724489 · 10% owner

VV Manager LLC · CIK 0001735804 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 395,845

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The securities reported herein are held of record by Vida Ventures, LLC ("Vida"). VV Manager, LLC is the mananging member of Vida. As a result, VV Manager, LLC may be deemed to beneficially own the securities held by Vida. VV Manager, LLC is managed by five directors, each of who disclaim beneficial ownership over the securities held of record by Vida except to the extent of their pecuniary interest therein.

SEC source: 0000899243-18-013061 · doc4a.xml · nonDerivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 909,742

F1 · ownership.nature: The securities reported herein are held of record by Vivo Panda Fund, L.P. ("Vivo LP"). Vivo Panda, LLC ("Vivo LLC") is the sole general partner of Vivo LP. Mahendra G. Shah, Ph.D., is a managing member of Vivo LLC and has shared voting and investment power over the securities beneficially owned by Vivo LP and may therefore be deemed to have or share beneficial ownership of the securities held directly by Vivo LP. Each of Vivo LLC and Dr. Shah disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.

SEC source: 0001193805-18-000480 · e617861_4-homology.xml · derivative · entry 1

Flynn James E · CIK 0001352546 · Director · 10% owner · *Director by Deputization

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) · CIK 0001009258 · Director · 10% owner · *Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Through Deerfield Management Company, L.P.

Disclosed balance after: 31,160

Underlying: Common Stock · 31,160 shares

Expires 2028-03-27

F1 · shares: Cameron Wheeler, an employee of Deerfield Management Company, L.P. ("Deerfield Management"), serves as a director of the Issuer. The option granted to Cameron Wheeler and reported herein is held for the benefit, and at the direction, of Deerfield Management.

F2 · derivative.exercise_date: The option shall vest and become exercisable with respect to one-third of the shares on each of March 27, 2019, March 27, 2020 and March 27, 2021.

F1 · derivative.underlying_shares: Cameron Wheeler, an employee of Deerfield Management Company, L.P. ("Deerfield Management"), serves as a director of the Issuer. The option granted to Cameron Wheeler and reported herein is held for the benefit, and at the direction, of Deerfield Management.

F1 · balance_after: Cameron Wheeler, an employee of Deerfield Management Company, L.P. ("Deerfield Management"), serves as a director of the Issuer. The option granted to Cameron Wheeler and reported herein is held for the benefit, and at the direction, of Deerfield Management.

F1 · ownership.nature: Cameron Wheeler, an employee of Deerfield Management Company, L.P. ("Deerfield Management"), serves as a director of the Issuer. The option granted to Cameron Wheeler and reported herein is held for the benefit, and at the direction, of Deerfield Management.

F3 · ownership.nature: This Form 4 is being filed by the undersigned as well as the entity listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). James E. Flynn is the sole member of the general partner of Deerfield Management. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

SEC source: 0000899243-18-008919 · doc4.xml · derivative · entry 1

Rasty Siyamak · CIK 0001735450 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,780

Underlying: Common Stock · 30,780 shares

Expires 2028-03-27

F1 · derivative.exercise_date: The option vests in 48 equal monthly installments on the first day of each calendar month following March 27, 2018.

SEC source: 0000899243-18-008923 · doc4.xml · derivative · entry 1

Patterson Matthew R · CIK 0001401018 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,360

Underlying: Common Stock · 8,360 shares

Expires 2028-03-27

F1 · derivative.exercise_date: The option will vest in three equal annual installments beginning on March 27, 2019.

SEC source: 0000899243-18-008912 · doc4.xml · derivative · entry 1

GILLIS STEVEN · CIK 0001229592 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,160

Underlying: Common Stock · 31,160 shares

Expires 2028-03-27

F1 · derivative.exercise_date: The option will vest in three equal annual installments beginning on March 27, 2019.

SEC source: 0000899243-18-008909 · doc4.xml · derivative · entry 1

SHAH MAHENDRA · CIK 0001255449 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,160

Underlying: Common Stock · 31,160 shares

Expires 2028-03-27

F1 · derivative.exercise_date: The option will vest in three equal annual installments beginning on March 27, 2019.

SEC source: 0000899243-18-008932 · doc4.xml · derivative · entry 1

Thistle Mary · CIK 0001317917 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,160

Underlying: Common Stock · 31,160 shares

Expires 2028-03-27

F1 · derivative.exercise_date: The option will vest in three equal annual installments beginning on March 27, 2019.

SEC source: 0000899243-18-008914 · doc4.xml · derivative · entry 1

Smith W Bradford · CIK 0001317678 · CFO, Treasurer & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,711

Underlying: Common Stock · 49,711 shares

Expires 2028-03-27

F1 · derivative.exercise_date: The option vests in 48 equal monthly installments on the first day of each calendar month following March 27, 2018.

SEC source: 0000899243-18-008931 · doc4.xml · derivative · entry 1

TZIANABOS ARTHUR · CIK 0001586226 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,376

Underlying: Common Stock · 92,376 shares

Expires 2028-03-27

F1 · derivative.exercise_date: The option vests in 48 equal monthly installments on the first day of each calendar month following March 27, 2018.

SEC source: 0000899243-18-008924 · doc4.xml · derivative · entry 1

Gregory Richard J. · CIK 0001629767 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,160

Underlying: Common Stock · 31,160 shares

Expires 2028-03-27

F1 · derivative.exercise_date: The option will vest in three equal annual installments beginning on March 27, 2019.

SEC source: 0000899243-18-008926 · doc4.xml · derivative · entry 1

Seymour Albert · CIK 0001735324 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,501

Underlying: Common Stock · 66,501 shares

Expires 2028-03-27

F1 · derivative.exercise_date: The option vests in 48 equal monthly installments on the first day of each calendar month following March 27, 2018.

SEC source: 0000899243-18-008930 · doc4.xml · derivative · entry 1

Wheeler Cameron · CIK 0001735323 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 31,160

Underlying: Common Stock · 31,160 shares

Expires 2028-03-27

F1 · derivative.exercise_date: The option will vest in three equal annual installments beginning on March 27, 2019.

F2 · ownership.nature: The Reporting person, a principal at Deerfield Management Company, L.P., has no pecuniary interest in the securities reported herein and disclaims beneficial ownership of such securities. The Reporting Person holds the option for the benefit, and at the direction, of Deerfield Management Company, L.P.

SEC source: 0000899243-18-008925 · doc4.xml · derivative · entry 1

PARMAR KUSH · CIK 0001664281 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,160

Underlying: Common Stock · 31,160 shares

Expires 2028-03-27

F1 · derivative.exercise_date: The option will vest in three equal annual installments beginning on March 27, 2019.